Trial Profile
A phase III multi-centre double-blind placebo controlled study analysing the efficacity and safety of daily administration of a P2Y12 inhibitor (Clopidogrel) for the treatment of locally advanced or metastatic pancreatic cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PANCREADOGREL
- 04 Jun 2021 Status changed to completed.
- 23 Jul 2019 Status changed from active, no longer recruiting to discontinued.
- 28 Aug 2017 Planned End Date changed from 1 Jan 2019 to 26 Jun 2018.